Asthma and lower airway diseaseSerum vitamin D levels and severe asthma exacerbations in the Childhood Asthma Management Program study
Section snippets
Study population
CAMP was a multicenter, randomized, double-blind, placebo-controlled trial established to investigate the long-term effects of commonly prescribed asthma treatment regimens. In total, 1,041 children were randomized to receive inhaled budesonide, inhaled nedocromil, or placebo. Participants were subsequently followed for a mean of 4.3 years, with lung function studies and questionnaires at regular intervals. Serum IgE levels and eosinophil counts were measured at the time of enrollment in the
Characteristics of the study population
The baseline characteristics of the study population stratified by vitamin D sufficiency are shown in Table I. Thirty-five percent of the children were vitamin D insufficient, as defined by a level of 30 ng/mL or less. In a univariate analysis vitamin D insufficiency was significantly associated with older age, higher BMI, and African American race. A higher proportion of the vitamin D–sufficient group was randomized to the budesonide treatment group, although the blood samples were drawn
Discussion
Our group previously reported an inverse relationship with vitamin D levels and several markers of asthma and allergy severity in Costa Rican children.9 The present data from the CAMP cohort of 1,024 children confirms the finding in the Costa Rican study that low vitamin D levels are associated with increased odds of asthma-related ED visits or hospitalization in the previous year. In this study we further demonstrate that after adjustment for age, sex, BMI, and baseline asthma severity,
References (30)
Circulating 25-hydroxyvitamin D levels indicative of vitamin D sufficiency: implications for establishing a new effective dietary intake recommendation for vitamin D
J Nutr
(2005)- et al.
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes
Am J Clin Nutr
(2006) - et al.
The urgent need to recommend an intake of vitamin D that is effective
Am J Clin Nutr
(2007) - et al.
Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol
Am J Clin Nutr
(2003) - et al.
Circulating vitamin D(3) and 25-hydroxyvitamin D in humans: An important tool to define adequate nutritional vitamin D status
J Steroid Biochem Mol Biol
(2007) - et al.
Anaphylaxis and vitamin D: a role for the sunshine hormone?
J Allergy Clin Immunol
(2007) - CDC National Center for Health Statistics. Asthma prevalence, health care use and mortality: United States, 2003-05....
- et al.
The global burden of asthma: executive summary of the GINA Dissemination Committee report
Allergy
(2004) - et al.
National Hospital Discharge Survey: 2005 annual summary with detailed diagnosis and procedure data
Vital Health Stat 13
(2007) Asthma
American Lung Association Lung Disease Data
(2008)
Acute exacerbations of asthma: epidemiology, biology and the exacerbation-prone phenotype
Clin Exp Allergy
Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense
J Immunol
Vitamin D decreases respiratory syncytial virus induction of NF-kappaB-linked chemokines and cytokines in airway epithelium while maintaining the antiviral state
J Immunol
Childhood asthma may be a consequence of vitamin D deficiency
Curr Opin Allergy Clin Immunol
Serum vitamin D levels and markers of severity of childhood asthma in Costa Rica
Am J Respir Crit Care Med
Cited by (413)
Vitamin D, acute respiratory infection, and Asthma/COPD
2023, Feldman and Pike's Vitamin D: Volume Two: Disease and TherapeuticsProtocol for the Vitamin D Oral Replacement in Asthma (VDORA) study
2022, Contemporary Clinical TrialsAssociation between serum 25-hydroxy vitamin D levels and severity of asthma
2022, Clinical Nutrition ESPENCitation Excerpt :Increased airway hyperresponsiveness, decreased pulmonary function, poorer asthma management, and steroid resistance have been linked to vitamin D insufficiency [5]. Insufficient vitamin D levels (defined as blood concentrations of less than 30 ng/ml) have been linked to an increased risk of severe asthma in children [6]. Most of these researches were conducted on children, and this link has not been well investigated in adults.
The Role of Comorbidities in Difficult-to-Control Asthma in Adults and Children
2022, Journal of Allergy and Clinical Immunology: In Practice
We acknowledge the Childhood Asthma Management Program (CAMP) investigators and research team, supported by the National Heart, Lung, and Blood Institute, for collection of CAMP Genetics Ancillary Study data. All work on data collected from the CAMP Genetics Ancillary Study was conducted at the Channing Laboratory of the Brigham and Women's Hospital under appropriate CAMP policies and human subject's protections. The CAMP Genetics Ancillary Study is supported by U01 HL075419, U01 HL65899, P01 HL083069, R01 HL086601, and T32 HL07427 from the National Heart, Lung, and Blood Institute(NHLBI)/National Institutes of Health. We also acknowledge the Asthma Clinical Research Network (ACRN) investigators and research teams supported by U01 HL51510, U01 HL51834, U01 HL51831, U01 HL51845, U01 HL 51843, M01 RR00079, and M01 RR03186 from the NHLBI. This work was also supported by National Institutes of Health grant R21HL089842.
Disclosure of potential conflict of interest: A. L. Fuhlbrigge is on an advisory board for and has given talks for Merck and has received continuing medical education from Advanced Health Media, funded through GlaxoSmithKline. B. W. Hollis has consulted for DiaSorin and has received research support from the National Institutes of Health. R. S. Zeiger has consulted for AstraZeneca, Aerocrine, Genentech, Novartis, Merck, Schering-Plough, and MedImmune and has received indirect research support from Aerocrine, Genentech, GlaxoSmithKline, Merck, AstraZeneca, and TEVA Pharmaceuticals. A. A. Litonjua has received research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.
- ∗
These authors contributed equally to this work.
- ‡
Members of the Childhood Asthma Management Program Research Group are detailed in this article's Online Repository at www.jacionline.org.